Matt Labenski
@LabenskiMatt
Followers
33
Following
54
Media
0
Statuses
29
Joined September 2019
RT @jnanatx: Attending the @AcsMedi @EuroMedChem Medicinal Chemistry Frontiers meeting next week? Join us for Justin Rettenmaier’s presenta….
0
3
0
RT @jnanatx: Attending @CHI_Healthtech’s #DrugDiscoveryChemistry Conference? Stop by our presentation to learn how we’re leveraging our RAP….
0
3
0
RT @jnanatx: We are incredibly excited to welcome so many wonderful new team members to Jnana. Interested in being a part of a team advanci….
0
2
0
RT @Pthompsn1018: Outstanding review by Juswinder Singh. The Ascension of Targeted Covalent Inhibitors
pubs.acs.org
Covalent drugs have made a major impact on human health but until recently were shunned by the pharmaceutical industry over concerns about the potential for toxicity. A resurgence has occurred driven...
0
2
0
RT @NatureBiotech: To celebrate outstanding leaders in the biotech industry for #WomensHistoryMonth, today we recognize Joanne Kotz, co-fou….
0
11
0
RT @jnanatx: Today, we recognize people around the world with rare diseases. We are advancing JNT-517 as development candidate and potentia….
0
4
0
RT @SchreiberStuart: A human biology-based drug discovery effort coupled with a powerful binder-based chemoproteomics Platform is paving a….
0
7
0
RT @jnanatx: Excited to announce we are advancing JNT-517 as a Development Candidate and potential first-in-class oral treatment for PKU ht….
0
6
0
RT @jnanatx: Jnana CEO, @JoanneKotz, will be presenting at #JPM22 on our next gen chemoproteomic platform to pursue hard-to-drug targets. L….
0
6
0
RT @jnanatx: We’re applying our RAPID platform to address hard-to-drug targets including SLC transporters, scaffold proteins, transcription….
0
3
0
RT @PeterKolchinsky: Peters’ alternative to HR3 represents progress in debate on needed healthcare reforms. Everyone in biotech, please rea….
sandiegouniontribune.com
Peters has represented Coronado, Poway and San Diego in Congress since 2013. He serves on the House Energy and Commerce Committee, which has jurisdiction over health care. He lives in Bird Rock.Las…
0
12
0
RT @jnanatx: Our next generation chemoproteomic RAPID platform enables us to address well-validated but hard-to-drug targets, including the….
0
1
0
RT @jnanatx: Fierce Biotech digs into our Series B news today:.
fiercebiotech.com
After years chasing a hard-to-drug group of targets called solute carriers, Jnana Therapeutics is revealing its lead program and a new $50 million financing to get it into the clinic. | After years...
0
1
0
RT @jnanatx: Jnana Therapeutics closes $50 million Series B financing to advance lead PKU program and small molecule pipeline based on next….
jnanatx.com
– Funds progression of lead program, an oral approach to treating phenylketonuria (PKU), into the clinic – – Supports expanded application of chemoproteomic RAPID platform for small-molecule discov...
0
4
0